Search | Invivogen

#Custom Services

Custom Cell Line Development Service

Our custom cell line development service is designed to support your specific experimental goals

Overexpression confirmation

Biological activity validation

Stability testing

#Custom Services

PRR Compound Screening and Profiling

Our screening service can assess activation or inhibition of innate immune pathways by pattern recognition receptors

Level 1 Compound Profiling Example Figure

Level 2 Compound Dose Response Example Figure

#Custom Services

Custom Cloning Service

Specialized plasmids designed to meet your unique experimental needs

Default product image

VET-SAP® saponin adjuvant

Saponin vaccine adjuvant - CAS #8047-15-2

Default product image

#Custom Services

Cytokines Compound Screening

Our profiling service enables the detection of bioactive effects in your samples.

Dose-response of HEK-Blue™-derived cells to compound of interest

Dose-dependent inhibition of HEK-Blue™-derived cell response using the compound of interest

CL429 VacciGrade™ - TLR2 & NOD2-based Adjuvant

Pam2C-conjugated murabutide

Dose-dependent NF-κB response to CL429 in HEK-Blue™ hTLR2 and HEK-Blue™ hNOD2 cells

CL429 chemical structure

Pam3CSK4 VacciGrade™ - TLR2/TLR1-based Adjuvant

Synthetic triacylated lipopeptide | Th1 response

Evaluation of NF-κB activation with Pam3CSK4

Specificity of Pam3CSK4 activation

ODN 1585 VacciGrade™ - TLR9-based Adjuvant

CpG ODN, Class A (Mouse) | Th1 response

Dose-dependent NF-κB response of ODN 1585 in HEK-Blue™ mTLR9 cells

NF-κB and IRF responses of ODN 1585 in THP1-Dual™ hTLR9 cells

M-TriLYS - NOD2 Agonist

Synthetic muramyl tripeptide

M-TriLYS dose-dependent activation of NOD2

CL413 VacciGrade™ - TLR2 & TLR7-based Adjuvant

Chimeric molecule | Th1/Th2 response

Tumor growth after CL413 or CL401 treatment

Survival curves for untreated as well as CL413- or CL401-treated mice

CL413 chemical structure

CL401 VacciGrade™ - TLR2 & TLR7-based Adjuvant

Pam2C-conjugated 8-hydroxyadenine| Th1/Th2 response

Tumor growth after CL413 or CL401 treatment

Survival curves for untreated as well as CL413- or CL401-treated mice

Anti-OVA mIgG levels at 15, 30 and 45 days after the initial immunization in different groups.

Anti-OVA total IgG, IgG1, and IgG2a levels 45 days after the initial immunization in different groups.

Quil-A® adjuvant

Saponin vaccine adjuvant

Default product image

PGN-SAndi ultrapure peptidoglycan - NOD2 Agonist

Insoluble peptidoglycan from S. aureus

Dose-dependent NF-κB response to PGN-SAndi Ultrapure in HEK-Blue™ hNOD2 cells

PGN-ECndss ultrapure peptidoglycan - NOD1/NOD2 Agonist

Soluble sonicated peptidoglycan from E. coli K12

Dose-dependent NF-κB response of PGN-ECndss Ultrapure in HEK-Blue™ hNOD1 and HEK-Blue™ hNOD2 cells

PGN-ECndi Ultrapure Peptidoglycan - NOD2 Agonist

Insoluble peptidoglycan from E. coli K12

Dose-dependent NF-κB response to PGN-ECndi Ultrapure in HEK-Blue™ hNOD1 and HEK-Blue™ hNOD2 cells

M-TriDAP - NOD1/NOD2 Agonist

MurNAc-L-Ala-gamma-D-Glu-mDAP - PGN-like molecule

NF-κB responses of HEK-Blue™ hNOD1 cells to various PRR agonists and cytokines

NF-kB response of HEK-Blue™ hNOD2 cells to various PRR agonists and cytokines

Murabutide - NOD2 Agonist

Synthetic derivative of muramyldipeptide

Murabutide dose-dependent activation of NOD2

N-Glycolyl-MDP - NOD2 Agonist

N-glycolylated muramyldipeptide

N-Glycolyl-MDP dose-dependent activation of NOD2

L18-MDP - NOD2 Agonist

Muramyldipeptide with a C18 fatty acid chain

L18-MDP dose-dependent activation of NOD2

MDP Control - NOD2 Agonist Negative Control

Negative control for MDP - Muramyldipeptide (L-L isomer, inactive)

Dose-dependent NF-κB response in HEK-Blue™ hNOD2 cells